<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890719</url>
  </required_header>
  <id_info>
    <org_study_id>EGRADICATE</org_study_id>
    <nct_id>NCT02890719</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.</brief_title>
  <acronym>EGRADICATE</acronym>
  <official_title>Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot, single center, open-label study to evaluate the efficacy and tolerability of
      Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant
      recipients with hepatitis C recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    impossibility of supplying the medication in research of the study by the pharmaceutical
    company that gave it to the trial
  </why_stopped>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Sustained virological response 12 w (SVR24) defined as HCV-RNA undetectable at post-treatment week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>4 weeks and 24 weeks post-treatment</time_frame>
    <description>Sustained virological response 12 ( SVR12) defined as HCV-RNA undetectable at post-treatment weeks 4 and , 24 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the beneficial effects of antiviral therapy on renal function.</measure>
    <time_frame>24 weeks post-treatment</time_frame>
    <description>creatinine sample analyses blood analyses in all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of therapy in kidney function.</measure>
    <time_frame>24 weeks post-treatment</time_frame>
    <description>Elevation Transaminases blood analyses in all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of this combination in liver transplant recipients.</measure>
    <time_frame>Every visit</time_frame>
    <description>Serious advers events evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1A and 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir 100 mg/day</intervention_name>
    <description>Grazoprevir 100 mg/ day 12 weeks</description>
    <arm_group_label>Genotype 1B</arm_group_label>
    <other_name>J05AX68 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir 50 mg/d</intervention_name>
    <description>Elbasvir 50 mg/day 12 weeks</description>
    <arm_group_label>Genotype 1B</arm_group_label>
    <other_name>J05AX68 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir 100 mg/day</intervention_name>
    <description>Grazoprevir 100 mg/day 16 weeks</description>
    <arm_group_label>Genotype 1A and 4</arm_group_label>
    <other_name>J05AX68 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir 50 mg/day</intervention_name>
    <description>Elbasvir 50 mg/d 16 weeks</description>
    <arm_group_label>Genotype 1A and 4</arm_group_label>
    <other_name>50mg J05AX68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 1200 mg/day</intervention_name>
    <description>Ribavirin 1200 mg/day 16 weeks</description>
    <arm_group_label>Genotype 1A and 4</arm_group_label>
    <other_name>J05AB04 1200 mg/d</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 78 year-old.

          -  Previous liver transplantation(more than 6 month).

          -  Genotype 1 and 4 infection.

          -  Hepatitis C recurrence defined by the presence of abnormal liver function test,
             positive HCV-RNA, histological signs of hepatitis C recurrence.

          -  Viral load ≥10000UI/mL.

          -  Immunosuppression with tacrolimus and/or mycophenolate (Prednisone use is allowed at
             low dose, ≤10 mg/d).

          -  Treatment naïve or treatment experienced (Peg-RBV or triple therapy).

        Exclusion Criteria:

          -  Genotype 2, 3, 5 or 6 infection.

          -  Decompensated cirrhosis defined by the presence of actual or previous history of
             clinical decompensation including ascites, hepatic encephalopathy, variceal bleeding
             or spontaneous bacterial peritonitis, or a Child-Pugh B or C.

          -  Hepatocellular carcinoma after liver transplantation.

          -  Total bilirubin &gt; 3 mg/dL.

          -  Immunosuppression with cyclosporine or an mTOR inhibitor (everolimus or sirolimus).

          -  Severe extrahepatic diseases: cardiovascular, respiratory, cerebrovascular and poorly
             controlled diabetes.

          -  Platelets &lt; 75 x 109 cells/L.

          -  Neutrophil count &lt; 0.5 x 109 cells/L.

          -  Hemoglobin &lt; 9 g/dL.

          -  Albumin &lt; 3g/dL.

          -  HIV infection.

          -  Hepatitis B infection.

          -  Active intake of toxic amounts of alcohol or recreational drugs.

          -  Females who are pregnant, become to be pregnant or breastfeeding or males whose
             partners are pregnant, become to be pregnant or breastfeeding.

          -  Intake of disallowed medications including(but not limited to):

               1. Antibiotics: clarithromycin, erythromycin, telithromycin, nafcillin, rifampin

               2. Antifungals: itraconazole, ketoconazole, voriconazole

               3. Antihypertensives: nifedipine

               4. Anticonvulsants: carbamazepine, phenytoin, phenobarbital

               5. Bosentan

               6. Modafinil

               7. St.Jonh's Wort

               8. Immunosuppressants: cyclosporin, everolimus, sirolimus

               9. Diabetes agents: glibenclamide, glyburide

              10. Lipid lowering agents: gemfibrozil

              11. Eltrombopag

              12. Lapatinib

              13. HIV medications: efavirenz, etravirine, all ritonavir boosted and unboosted HIV
                  protease inhibitors

              14. Statins: simvastatin, fluvastatin, rosuvastatin at doses greater than 10 mg/d,
                  atorvastatin at doses greater than 10 mg/d.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Xavier Forns</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

